BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
- Company Intends to Refinance the Remainder of Secured Debt in 2017 -
- Continues Commitment to De-Levering the Company -
NEWARK, Calif., April 04, 2017 -- Depomed Inc., (NASDAQ:DEPO) today announced that, in accordance with its stated plans and the terms of the secured debt facility with Deerfield and Pharmakon Advisors, LP, the company prepaid $100 million of principal amount of its $475 million secured indebtedness. In addition, Depomed paid a prepayment fee of $4 million.
Under the terms of the 7-year loan agreement, which matures in 2022, Depomed intends to refinance the remainder of the $375 million secured indebtedness in 2017.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to the company’s expectations regarding refinancing and the risks detailed in the Company’s Securities and Exchange Commission filings, including the Company’s most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the Company’s plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payers we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000
